// App-Quantinova.ai

738 : Prospective Validation of the Systemic Sclerosis Skin Symptoms Patient-Reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Researchers

Presenter

  • Ada Man

Principal Investigators

  • Nancy Dgetluck

  • Barbara White

Medical Centers

  • Physiology, University of Manitoba, Winnipeg, Canada

  • Biostatistics, Corbus Pharmaceuticals, Norwood, MA

  • Corbus Pharmaceuticals, Norwood, MA

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ajulemic acid

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Prospective

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved